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Visual contrast sensitivity is associated with
the presence of cerebral amyloid and tau
deposition
Shannon L. Risacher,1,2 Darrell WuDunn,3 Eileen F. Tallman,1,2 John D. West,1,2
Sujuan Gao,2,4 Martin R. Farlow,2,5 Jared R. Brosch,2,5 Liana G. Apostolova1,2,5 and
Andrew J. Saykin1,2
Visual deficits are common in neurodegenerative diseases including Alzheimer’s disease. We sought to determine the association be-
tween visual contrast sensitivity and neuroimaging measures of Alzheimer’s disease-related pathophysiology, including cerebral
amyloid and tau deposition and neurodegeneration. A total of 74 participants (7 Alzheimer’s disease, 16 mild cognitive impair-
ment, 20 subjective cognitive decline, 31 cognitively normal older adults) underwent the frequency doubling technology 24-2 exam-
ination, a structural MRI scan and amyloid PET imaging for the assessment of visual contrast sensitivity. Of these participants, 46
participants (2 Alzheimer’s disease, 9 mild cognitive impairment, 12 subjective cognitive decline, 23 cognitively normal older
adults) also underwent tau PET imaging with [18F]flortaucipir. The relationships between visual contrast sensitivity and cerebral
amyloid and tau, as well as neurodegeneration, were assessed using partial Pearson correlations, covaried for age, sex and race and
ethnicity. Voxel-wise associations were also evaluated for amyloid and tau. The ability of visual contrast sensitivity to predict amyl-
oid and tau positivity were assessed using forward conditional logistic regression and receiver operating curve analysis. All analyses
first were done in the full sample and then in the non-demented at-risk individuals (subjective cognitive decline and mild cognitive
impairment) only. Significant associations between visual contrast sensitivity and regional amyloid and tau deposition were
observed across the full sample and within subjective cognitive decline and mild cognitive impairment only. Voxel-wise analysis
demonstrated strong associations of visual contrast sensitivity with amyloid and tau, primarily in temporal, parietal and occipital
brain regions. Finally, visual contrast sensitivity accurately predicted amyloid and tau positivity. Alterations in visual contrast sensi-
tivity were related to cerebral deposition of amyloid and tau, suggesting that this measure may be a good biomarker for detecting
Alzheimer’s disease-related pathophysiology. Future studies in larger patient samples are needed, but these findings support the
power of these measures of visual contrast sensitivity as a potential novel, inexpensive and easy-to-administer biomarker for
Alzheimer’s disease-related pathology in older adults at risk for cognitive decline.
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Introduction
Alzheimer’s disease is a serious health concern associated
with aging. The most common form of age-related demen-
tia, Alzheimer’s disease affects >5.7 million people in the
USA, a number expected to rise to 14 million in 2050
(Alzheimer’s Association, 2019). Currently, no disease-
modifying drugs are available to treat Alzheimer’s disease.
Many researchers believe that early intervention is key to
the success of any future treatment. Thus, a great deal of
investigation has been focused on identifying biological
markers, or biomarkers, of Alzheimer’s disease in early
prodromal or preclinical stages of disease. Neuroimaging
tools, including MRI to study brain structure and function,
as well as PET imaging to measure the accumulation of
the two pathological hallmarks of Alzheimer’s disease,
amyloid-beta plaques and tau neurofibrillary tangles, are
key tools that have been identified for the early detection
of Alzheimer’s disease-related changes (Sperling et al.,
2011; Teipel et al., 2015; Jack et al., 2018). However,
these neuroimaging methods have limited availability and
are expensive, restricting their use in widespread screening.
Thus, many researchers are actively engaged in studies to
identify peripheral biomarkers that are cost-effective, non-
invasive and easy to administer.
In addition to the well-known cognitive effects related
to Alzheimer’s disease, patients with Alzheimer’s disease
often show profound changes in sensory and perceptual
processing, including in vision, smell, auditory function
and motor function, among other changes (Albers et al.,
2015). In the visual domain, patients with Alzheimer’s
disease have been reported to show alterations in colour
vision and pupillary response, among other changes. In
addition, we and others have observed that visual con-
trast sensitivity, as measured using frequency doubling
technology (FDT), was impaired in prodromal and mild
clinical Alzheimer’s disease (Cronin-Golomb et al., 1991;
Cormack et al., 2000; Crow et al., 2003; Risacher et al.,
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2013; Valenti, 2013; Polo et al., 2017) and linked to fu-
ture risk to dementia (Fischer et al., 2016; Ward et al.,
2018). Patients with Alzheimer’s disease and those in pro-
dromal stages, such as mild cognitive impairment (MCI),
show thinning of retinal layers, including the retinal nerve
fibre layer, and loss of retinal ganglion cells (Coppola
et al., 2015). Previous studies have suggested an associ-
ation between retinal nerve fibre layer and other retinal
layer thinning, as well as vascular changes, and amyloid
deposition on PET (Snyder et al., 2016; Santos et al.,
2018; van de Kreeke et al., 2020), while others have not
(Haan et al., 2019; Jung et al., 2019; van de Kreeke
et al., 2019). Some animal models of Alzheimer’s disease
have shown the accumulation of amyloid-beta, and its
precursor, amyloid precursor protein, and hyperphos-
phorylated tau in the retina (Koronyo-Hamaoui et al.,
2011; Koronyo et al., 2012; Chiasseu et al., 2017;
Koronyo et al., 2017; Grimaldi et al., 2018). A study by
Koronyo-Hamaoui et al. (2011) demonstrated that amyl-
oid deposition on the retina occurred concurrently with
amyloid deposition in the brain. Post-mortem studies of
human patients have shown mixed results, with some
showing pathological amyloid and tau accumulation in
the retinas of patients with Alzheimer’s disease and others
not observing such changes (Koronyo-Hamaoui et al.,
2011; Williams et al., 2017; den Haan et al., 2018).
Recent attempts to visualize amyloid accumulation in the
retina of patients with MCI and Alzheimer’s disease have
demonstrated sensitivity for detecting plaques that were
later confirmed on autopsy (Koronyo et al., 2017).
Overall, these findings suggest that the assessment of ret-
inal structure and function, as well as assessments of ret-
inal amyloid accumulation, might be promising peripheral
markers of central amyloid and tau pathology.
In the present report, we evaluated the relationship be-
tween FDT measures and cerebral amyloid and tau depos-
ition, measured using PET. We hypothesize that contrast
sensitivity will be associated with amyloid and tau depos-
ition on PET. First, we assessed the relationship of FDT
performance with amyloid and tau across the full cohort,
which includes cognitively normal older adults (CN), par-
ticipants with subjective cognitive decline (SCD) and
patients with MCI and Alzheimer’s disease. Then, to deter-
mine the sensitivity of this test to changes in participants
at high risk for Alzheimer’s disease, we evaluated the rela-
tionship of FDT with amyloid and tau in only SCD and
MCI participants. Finally, we determined the power of
FDT measures to predict amyloid or tau positivity.
Materials and methods
Participants
A total of 74 older adults (age 50þ years) were recruited
from the Indiana Memory and Aging Study cohort fol-
lowed by the Indiana Alzheimer Disease Center to
undergo advanced PET and MRI neuroimaging and vis-
ual testing. Participants included 7 patients diagnosed
with Alzheimer’s disease using standard criteria
(McKhann et al., 2011); 16 participants diagnosed with
MCI using previously established criteria (Petersen,
2004); 20 older adults characterized as SCD according to
the following criteria: elevated levels of subjective mem-
ory concerns on the 20-item Cognitive Change Index,
reflected as a score of 20 on the first 12 items, with or
without increased levels of informant-based concerns
(Jessen et al., 2014; Rattanabannakit et al., 2016), and
without a measurable cognitive deficit; and 31 CN with-
out significant memory concerns (12-item Cognitive
Change Index total<20) and without a significant per-
formance deficit on cognitive testing. The participants
underwent detailed neuropsychological testing, primarily
using the Uniform Dataset 3 (Weintraub et al., 2018),
along with the Rey Auditory Verbal Learning Test, Digit
Symbol Substitution and animal and vegetable fluency.
However, some individuals did not receive the Uniform
Dataset 3 but instead underwent a comprehensive neuro-
psychological battery (Saykin et al., 2006; Risacher et al.,
2013) with some overlapping tests (Craft Stories, animal
fluency, digit span and Trail Making A and B) and other
non-overlapping tests, including the California Verbal
Learning Test. We combined the Rey Auditory Verbal
Learning Test and California Verbal Learning Test results
into a ‘list learning z-score’ for both immediate total re-
call and delayed recall by creating a z-score relative to
CN participants from the larger Indiana Memory and
Aging study not included in this analysis, adjusted for
age, sex and years of education. Finally, all participants
received either a Mini-Mental State Examination or
Montreal Cognitive Assessment. The total scores from
the Mini-Mental State Examination were converted to
Montreal Cognitive Assessment total scores using the
method described in Trzepacz et al. (2015).
Due to the nature of the study, participants with macu-
lar degeneration, severe cataracts, primary open-angle
glaucoma, or diabetic retinopathy were excluded from
the study. In addition, one participant had glaucoma in
only one eye and, thus, only data from the non-glau-
comatous eye were used. All analyses were run with and
without those with suspected normal tension glaucoma,
and all results were consistent. Thus, those with sus-
pected normal tension glaucoma were included in the
analysis to be more representative of the at-risk
population.
All procedures were approved by the Indiana
University School of Medicine Institutional Review Board,
and informed consent was obtained according to the
Declaration of Helsinki and the Belmont Report.
Amyloid PET
Amyloid PET scans were done with either [18F]florbetapir
(Amyvid, Eli Lilly and Co.) or [18F]florbetaben
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(Neuraceq, Piramal Ltd.). For the [18F]florbetapir scans,
10mCi of [18F]florbetapir was injected intravenously
and, after a 50-min uptake period, participants were
imaged on a Siemens mCT for 20min using continuous
listmode data acquisition. For the [18F]florbetaben scans,
8mCi of [18F]Florbetaben was injected intravenously
and, after a 90-min uptake period, data were acquired
for 20min using continuous listmode acquisition on a
Siemens mCT. A computed tomography scan was
acquired for scatter and attenuation correction for both
types of amyloid tracers. Listmode data were subsequent-
ly rebinned into four 5-min frames for both tracers, and
reconstructions were conducted on the software platform
(Siemens, Knoxville, TN, USA). Ordered subset expect-
ation maximization was applied, using parameters from
the Alzheimer’s Disease Neuroimaging Initiative protocol
(http://adni.loni.usc.edu), with corrections for scatter and
random coincidence events, attenuation and radionuclide
decay. Using Statistical Parametric Mapping 8, the four
5-min frames were spatially aligned to each participant’s
individual magnetization-prepared rapid gradient-echo
scan, motion corrected, normalized to Montreal
Neurologic Institute space, and averaged to create a 50-
to 70-min static image for [18F]florbetapir scans or a 90-
to 110-min static image for [18F]florbetaben scans. Then,
standardized uptake value ratio (SUVR) images were cre-
ated by intensity normalizing to the whole cerebellum for
bother tracers. The whole cerebellum and cortical regions
of interest were taken from the Centiloid project (http://
www.gaain.org/centiloid-project/; Klunk et al., 2015). The
resulting SUVR images were converted to Centiloid units
as previously described (Klunk et al., 2015; Risacher
et al., 2017; Rowe et al., 2017; Navitsky et al., 2018).
Finally, the [18F]florbetapir and [18F]florbetaben Centiloid
scans were smoothed using an 8-mm full-width half max-
imum Gaussian kernel.
Regional [18F]florbetapir and [18F]florbetaben data in
Centiloid units were extracted from a global cortical
regions of interest from the Centiloid project (Klunk
et al., 2015; Risacher et al., 2017; Rowe et al., 2017;
Navitsky et al., 2018). Global cortical Centiloid units
21.02 was considered as amyloid-beta positive, as this
cut-off best predicted the SUVR cut-offs produced by UC
Berkeley in the Alzheimer’s Disease Neuroimaging
Initiative (SUVR> 1.11 for [18F]Florbetapir and
SUVR> 1.08 for [18F]Florbetaben, data not shown).
[18F]Flortaucipir PET
Of the 74 individuals, 46 individuals also underwent
[18F]flortaucipir scans. Briefly, 10mCi of
[18F]flortaucipir was injected intravenously; after a 75-
min uptake, participants were imaged for 30min using
continuous listmode data acquisition on a Siemens mCT,
rebinned into six 5-min frames and reconstructed using
standard scanner software (Siemens), using ordered subset
expectation maximization, with correction for scatter and
random coincident events, attenuation and radionuclide
decay. Using Statistical Parametric Mapping 8, the middle
four 5-min frames (80–100min) were motion corrected,
normalized to Montreal Neurologic Institute space, aver-
aged to create an 80- to 100-min static image, intensity
normalized to the cerebellar crus to create SUVR images
and smoothed with an 8-mm full-width half maximum
Gaussian kernel.
[18F]Flortaucipir SUVR was extracted from target
regions known to show tau binding in Alzheimer’s dis-
ease. Regions of interest were generated from participant-
specific parcellations for each individual from FreeSurfer
v5.1. Specifically, bilateral volume-weighted mean SUVR
values were extracted from the medial temporal lobe
(MTL, average of entorhinal cortex, fusiform and para-
hippocampal gyri), the lateral temporal lobe (LTL, aver-
age of banks of the superior temporal sulcus, inferior
temporal gyri, middle temporal gyri, superior temporal
gyri, transverse temporal pole) and the inferior parietal
lobe.
Structural MRI
Accelerated 3-dimensional magnetization-prepared rapid
gradient-echo scans were collected on a 3-T Siemens
Prisma scanner using the Alzheimer’s Disease
Neuroimaging Initiative-2 sequence (http://adni.loni.usc.
edu). Scans were coregistered to a Montreal Neurologic
Institute template and segmented using Statistical
Parametric Mapping 8 to create parameters for PET scan
processing described above. Scans were also processed
using FreeSurfer version 5.1 to create regions of interest
for extracting [18F]Flortaucipir SUVR and for the analysis
of selected regional atrophy measures, specifically lobar
(frontal, parietal, temporal and occipital) grey matter vol-
ume estimates.
Frequency doubling technology
Participants in this study underwent the FDT-2 24-2 vis-
ual field contrast sensitivity threshold examination (Welch
Allyn, Skaneateles Falls, NY, USA), which evaluates 55
visual field regions in the right eye, followed by 55
regions in the left eye with 24 coverage, a stimulus size
of 5, a spatial frequency of 0.5 cycles per degree and a
temporal frequency of 18Hz (Zeppieri and Johnson,
2008). The results of this test provide a single measure of
contrast sensitivity threshold (in decibels) at each of the
110 regions (55 right eye, 55 left eye) as previously
described (Turpin et al., 2003; McKendrick and Turpin,
2005). In addition to the threshold values for each re-
gion, a summary measure of general contrast sensitivity
across the visual field is reported for each eye, referred to
as the mean deviation in contrast sensitivity. A lower
mean deviation represents poorer contrast sensitivity per-
formance. In addition, because the 24-2 threshold visual
field test is iterative, examination duration (in seconds)
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represents a measure of contrast sensitivity performance,
as more iterations (longer examination time) are needed
in those with poorer contrast sensitivity. Thus, a longer
examination time represents poorer contrast sensitivity
performance. Finally, reliability tests are completed,
including estimations of fixation errors, false positive
errors and false negative errors, presented as previously
described (Anderson and Johnson, 2003; Zeppieri and
Johnson, 2008). Three participants had >50% errors in
a single eye, thus that data were excluded from further
analysis and only the eye without >50% errors was
included. All visual testing was done blinded to
diagnosis.
Statistical analysis
Differences between groups in demographic variables
were evaluated using an analysis of variance (ANOVA)
for continuous measures and chi-square for non-continu-
ous measures in the maximal sample for each modality.
Neuropsychological, clinical performance and basic imag-
ing variables were evaluated using an analysis of covari-
ance (ANCOVA) model, covaried for age, sex, race/
ethnicity, years of education (neuropsychological tests
only) and total intracranial volume (MRI variable only),
using Bonferroni correction for multiple comparisons.
The amyloid measures and examination duration were
transformed using a natural log to create normally dis-
tributed variables. Mean deviation in contrast sensitivity
was normally distributed without transformation. Tau
SUVR measures were non-normal regardless of trans-
formation type. Thus, regional tau SUVR measures were
transformed using a rank-based normal transformation
with Blom’s formula. The associations between FDT vari-
ables and the natural log of cortical amyloid, as well as
transformed MTL, LTL and inferior parietal gyri tau,
were evaluated using partial Pearson correlations, adjust-
ing for age, sex and race/ethnicity. The associations be-
tween FDT variables and lobar atrophy measures were
evaluated using a partial Pearson correlation, covaried for
age, sex and intracranial volume. Analyses were con-
ducted in both the full sample and SCD and MCI only.
Next, the strongest associated FDT variable for the
amyloid and tau analyses (duration and mean deviation,
respectively) were entered in voxel-wise regressions and
masked for grey and white matter regions, in Statistical
Parametric Mapping 8 to evaluate the whole brain associ-
ation pattern between these FDT measures and amyloid
and tau, covaried for age, sex and race/ethnicity. A
voxel-wise threshold of P-value <0.05 family-wise error-
corrected for multiple comparisons and minimum cluster
size (k)¼ 10 voxels was considered significant in the anal-
yses across all participants and in SCD and MCI only
for amyloid. The voxel-wise analyses of tau in patients
with SCD and MCI only were thresholded at a cluster-
wise P-value <0.05 family-wise error-corrected for mul-
tiple comparisons due to the reduced number of
participants in this analysis (n¼ 21). Finally, the ability
of the FDT variables most strongly associated to regional
amyloid and tau (duration and mean deviation, respect-
ively) to predict amyloid and tau positivity, defined as
global cortical Centiloid units 21.02 and Braak stage
4 on either hemisphere (Schwarz et al., 2018), respect-
ively, was evaluated using a receiver operating character-
istc (ROC) and forward conditional logistic regression
models, covaried for age, sex and race/ethnicity. All anal-
yses were done across all participants and in non-demen-
ted at-risk (SCDþMCI) participants only. In addition, all
analyses were repeated after removing participants who
were 3 SD above or below the whole group mean in ei-
ther FDT or neuroimaging variables. Removal of these
outliers did not significantly alter the relationships
observed; thus, all participants are included in the analy-
ses described below (data not shown). All non-voxel-wise
statistical analyses were performed using Statistical
Package for Social Sciences version 25 (https://www.ibm.
com/products/spss-statistics).
Data availability
The data for this study were collected at Indiana
University School of Medicine. Deidentified data specific
to this analysis are available to researchers upon request
through the Indiana Alzheimer Disease Center.
Results
Demographics and performance
Demographic and other sample characteristics are
described in Table 1. Significant differences among
groups in age, sex and race/ethnicity were observed
(P< 0.05; Table 1). However, education and APOE
genotype were not significantly different among groups.
Expected impairments in cognition were observed in
patients with MCI and Alzheimer’s disease across cogni-
tive domains, as well as increased self and informant
complaints (most P< 0.001, Table 1). SCD participants,
by design, did not show any significant differences from
CN in cognitive performance but showed significantly ele-
vated cognitive concerns on the Cognitive Change Index
(all P< 0.001; Table 1). Significant or trend differences in
contrast sensitivity performance were found across
groups, with lower performance in patients with MCI
and Alzheimer’s disease (P< 0.05; Table 1). In addition,
amyloid and tau deposition was significantly higher in
patients with MCI and Alzheimer’s disease relative to
SCD and CN, while hippocampal volume was lower, as
expected (P< 0.001; Table 1).
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Table 1 Sample description [mean (standard deviation)]
CN
(n531)
SCD
(n5 20)
MCI
(n516)
Alzheimer’s
disease (n5 7)
P-value Pair comparisons
(P<0.05 corrected*)
Age (years) 68.8 (4.8) 72.7 (6.4) 75.5 (8.5) 73.2 (10.6) 0.014 MCI>CN
Sex (M, F) 7, 24 9, 11 9, 7 4, 3 0.080 None
Years of education 16.9 (2.1) 17.0 (2.4) 15.4 (2.9) 17.0 (2.5) ns None
Race/ethnicity (% non-Hispanic
Caucasian) (%)
90.3 80.0 81.3 57.1 ns None
APOE e4 genotype (% e4þ)a (%) 51.7 45.0 40.0 85.7 ns None
MoCA total scoreb 26.6 (2.2) 26.2 (2.2) 22.4 (2.9) 15.8 (5.3) <0.001 CN, SCD>MCI>Alzheimer’s disease
CDR—memoryb 0.05 (0.12) 0.04 (0.15) 0.55 (0.25) 0.97 (0.00) <0.001 Alzheimer’s disease >MCI> SCD, CN
CDR—globalb 0.04 (0.12) 0.04 (0.15) 0.46 (0.13) 0.85 (0.24) <0.001 Alzheimer’s disease >MCI> SCD, CN
CDR—sum of boxesb 0.06 (0.23) 0.12 (0.28) 1.50 (1.25) 4.26 (1.19) <0.001 Alzheimer’s disease >MCI> SCD, CN
Digit span—forwardb,c 7.6 (2.1) 8.9 (2.4) 7.3 (2.1) 7.2 (1.8) ns None
Digit span—backwardb,c 6.7 (2.4) 7.5 (1.9) 5.3 (2.5) 5.1 (1.6) 0.040 None
Animal fluencyb,c 22.3 (4.8) 22.6 (4.8) 17.8 (3.7) 13.1 (4.7) <0.001 CN, SCD>MCI, Alzheimer’s disease
Vegetable fluencyb,d 16.6 (4.4) 14.9 (3.7) 10.6 (2.8) 6.4 (4.1) <0.001 CN, SCD>MCI, Alzheimer’s disease
Trail making A (s)b,c 33.7 (14.6) 28.5 (10.1) 39.8 (15.1) 61.5 (44.0) 0.002 Alzheimer’s disease > SCD, CN
Trail making B (s)b,e 83.2 (43.2) 76.6 (28.8) 144.9 (102.8) 244.0 (48.6) <0.001 Alzheimer’s disease >MCI> SCD, CN
Verbal list learning—
immediate (z-score)f,g
0.05 (0.88) 0.06 (0.94) 1.26 (0.93) 2.83 (0.72) <0.001 CN, SCD>MCI>Alzheimer’s disease
Verbal list learning—
delayed (z-score)f,g
0.09 (0.94) 0.10 (0.98) 1.61 (1.30) 3.48 (1.27) <0.001 CN, SCD>MCI>Alzheimer’s disease
Craft story recall—immediateb,h 21.4 (5.3) 22.8 (5.2) 14.3 (5.9) 8.0 (4.2) <0.001 CN, SCD>MCI, Alzheimer’s disease
Craft story recall—delayedb,i 19.0 (5.2) 20.0 (5.3) 11.3 (6.1) 3.7 (2.4) <0.001 CN, SCD, MCI>Alzheimer’s
disease; SCD>MCI
Benson figure copyb,j 15.6 (1.3) 15.1 (1.3) 15.7 (1.5) 10.5 (7.4) <0.001 CN, SCD, MCI>Alzheimer’s disease
Benson figure delayed recallb,k 11.9 (2.5) 12.8 (2.2) 8.1 (5.7) 0.8 (1.2) <0.001 CN, SCD, MCI>Alzheimer’s disease
MINT total score b,k 29.3 (2.2) 29.8 (2.4) 28.6 (3.6) 26.3 (5.7) ns None
Letter fluencyb,l 28.1 (6.0) 30.9 (8.4) 27.0 (7.4) 28.7 (14.3) ns None
CCI self—12-item totalb,m 16.0 (4.0) 26.6 (4.9) 34.5 (10.2) 36.3 (11.0) <0.001 Alzheimer’s disease, MCI, SCD>CN
CCI self—20-item totalb,m 25.1 (6.0) 39.8 (7.7) 53.8 (17.2) 56.0 (17.6) <0.001 MCI> SCD>CN; Alzheimer’s
disease >CN
CCI informant—12-item totalb,n 15.2 (5.7) 16.8 (5.4) 36.8 (11.6) 45.6 (9.7) <0.001 Alzheimer’s disease, MCI> SCD, CN
CCI informant—20-item totalb,n 24.4 (9.7) 26.3 (7.0) 58.5 (21.1) 76.7 (15.6) <0.001 Alzheimer’s disease, MCI> SCD, CN
Duration of FDT-2 examination (s)o 310.3 (9.5) 309.1 (7.9) 318.6 (13.7) 320.4 (16.3) 0.018 None
Mean deviation in
contrast sensitivityo
0.9 (2.4) 0.9 (2.7) 2.3 (3.8) 4.3 (6.2) 0.088 None
Pattern standard deviation in
contrast sensitivityo
2.9 (0.5) 3.1 (0.5) 3.7 (1.0) 3.9 (1.1) 0.005 Alzheimer’s disease, MCI>CN
Cortical amyloid Centiloido 2.4 (20.2) 21.5 (40.9) 54.3 (52.9) 98.2 (20.8) <0.001 Alzheimer’s disease, MCI>CN;
Alzheimer’s disease > SCD
Lateral temporal tau SUVRo,p 1.12 (0.6) 1.13 (0.6) 1.30 (0.35) 2.11 (0.50) <0.001 CN, SCD, MCI>Alzheimer’s disease
Hippocampal volumeq 3770.4 (356.4) 3821.2 (532.2) 3518.3 (589.1) 3007.5 (521.0) <0.001 CN, SCD, MCI>Alzheimer’s disease
APOE: apolipoprotein E; CCI: Cognitive Change Index; CDR: Clinical Dementia Rating Scale; F: female; M: male; MoCA: Montreal Cognitive Assessment; ns: .
*Bonferroni corrected.
aThree participants missing (2 CN, 1 MCI).
bCovaried for age, sex, education and race/ethnicity.
cFive participants missing (1 CN, 2 SCD, 1 MCI, 1 Alzheimer’s disease).
dEleven participants missing (3 CN, 2 SCD, 4 MCI, 2 Alzheimer’s disease).
eSeven participants missing (1 CN, 2 SCD, 1 MCI, 3 Alzheimer’s disease).
fTen participants missing (5 CN, 2 SCD, 2 MCI, 1 Alzheimer’s disease).
gCovaried for race/ethnicity; pre-adjusted for age, sex and education.
hNine participants missing (2 CN, 3 SCD, 3 MCI, 1 Alzheimer’s disease).
iTen participants missing (2 CN, 3 SCD, 3 MCI, 2 Alzheimer’s disease).
jTwenty participants missing (5 CN, 5 SCD, 7 MCI, 3 Alzheimer’s disease).
kTwenty-one participants missing (5 CN, 5 SCD, 7 MCI, 4 Alzheimer’s disease).
lTwenty-two participants missing (5 CN, 5 SCD, 8 MCI, 4 Alzheimer’s disease).
mTwenty-two participants missing (6 CN, 4 SCD, 8 MCI, 4 Alzheimer’s disease).
nTwenty-six participants missing (8 CN, 7 SCD, 8 MCI, 3 Alzheimer’s disease).
oCovaried for age, sex and race/ethnicity.
pTwenty-eight participants missing (8 CN, 8 SCD, 7 MCI, 5 Alzheimer’s disease).
qCovaried for age, sex, race/ethnicity and total intracranial volume.
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Contrast sensitivity associations
with regional amyloid
Across all participants, significant associations be-
tween mean deviation in contrast sensitivity and cor-
tical amyloid deposition [rp¼0.331, degrees of
freedom (df)¼ 69, P¼ 0.005; Fig. 1A] and between
examination duration and amyloid deposition in the
global cortex (rp¼ 0.452, df¼ 69, P< 0.001; Fig. 1B)
were observed. Within only individuals with either
SCD or MCI, significant associations between mean
deviation in contrast sensitivity and cortical amyloid
deposition (rp¼0.363, df¼ 31, P¼ 0.038; Fig. 1C)
and between examination duration and global cortical
amyloid (rp¼ 0.656, df¼ 31, P< 0.001; Fig. 1D) were
observed.
Contrast sensitivity associations
with regional tau
Significant associations between mean deviation in con-
trast sensitivity and transformed MTL tau (rp¼0.499,
df¼ 46, P¼ 0.001; Fig. 2A), LTL tau (rp¼0.596,
df¼ 46, P< 0.001; Fig. 2B) and inferior parietal lobule
tau (rp¼0.559, df¼ 46, P< 0.001; Fig. 2C) were
observed. In addition, examination duration was associ-
ated with all tau of these regions, including the MTL
(rp¼ 0.422, df¼ 46, P¼ 0.006; Fig. 2D), LTL (rp¼ 0.417,
df¼ 46, P¼ 0.007; Fig. 2E) and inferior parietal lobule
(rp¼ 0.444, df¼ 46, P¼ 0.004; Fig. 2F). In SCD and
MCI participants only, even stronger associations were
observed between mean deviation in contrast sensitivity
and transformed tau deposition in the MTL (rp¼0.728,
Figure 1 Visual contrast sensitivity is associated with regional cerebral amyloid deposition. Significant associations between visual
contrast sensitivity, measured as mean deviation in contrast sensitivity (A, P¼ 0.005) and examination duration (B, P< 0.001), and cortical
amyloid deposition were observed across all participants (n¼ 74). In SCD and MCI individuals only (n¼ 36), significant associations were
observed between cortical amyloid and mean deviation in contrast sensitivity (C, P¼ 0.038), as well as examination duration (D, P< 0.001).
Note that examination duration (indicated as the natural log of seconds needed to complete the examination) is a measure of contrast sensitivity
performance as the test is iterative and those with poorer contrast sensitivity take longer on the examination, while lower mean deviation scores
represent poorer contrast sensitivity performance. A and B include 31 CN (blue circles), 20 SCD (green triangles), 16 MCI (yellow squares), and
7 AD (red diamonds); C and D include 20 SCD (green triangles) and 16 MCI (yellow squares).
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df¼ 21, P¼ 0.001; Fig. 3A), LTL (rp¼0.775, df¼ 21,
P< 0.001; Fig. 3B) and inferior parietal lobule
(rp¼0.641, df¼ 21, P¼ 0.007; Fig. 3C). Finally, in
SCDþMCI participants only, examination duration
showed significant association with tau in the MTL
(rp¼ 0.616, df¼ 21, P¼ 0.011; Fig. 3D) and a trend for
an association with tau in the LTL (rp¼ 0.446, df¼ 21,
P¼ 0.084; Fig. 3E) and inferior parietal lobule
(rp¼ 0.429, df¼ 21, P¼ 0.097; Fig. 3F).
Contrast sensitivity associations
with regional atrophy
Temporal lobe grey matter volume was significantly asso-
ciated with both mean deviation in contrast sensitivity
(rp¼ 0.277, P¼ 0.020; Fig. 4A) and examination duration
(rp¼0.349, P¼ 0.003; Fig. 4B) in the full sample of
participants. Similarly, an association between temporal
lobe grey matter volume and mean deviation in contrast
sensitivity (rp¼ 0.418, P¼ 0.017; Fig. 4C) and examin-
ation duration (rp¼0.446, P¼ 0.011; Fig. 4D) was
observed in the at-risk cohort of SCDþMCI participants
only.
Voxel-wise associations of contrast
sensitivity with amyloid
Amyloid in widespread regions showed association with
examination duration, including in the lateral parietal
and temporal lobes, the occipital lobe and the frontal
lobe (Fig. 5A). When the analyses were limited to only
SCD and MCI participants, more focal associations were
observed between amyloid and examination duration,
including in the medial and lateral parietal lobes, the
temporal lobes and the occipital lobe (Fig. 5B).
Voxel-wise associations of contrast
sensitivity with tau
Significant associations between mean deviation in con-
trast sensitivity and tau deposition in widespread regions
of the posterior cortex, including the temporal and par-
ietal lobes, the occipital lobe and a few regions in the
frontal lobe (Fig. 6A), were observed. In SCD and MCI
participants only, a very similar pattern of regions was
significantly associated with mean deviation in contrast
sensitivity, albeit at a less stringent but still significant
threshold (cluster-wise versus voxel-wise P< 0.05 family-
wise error). Specifically, mean deviation in contrast
Figure 2 Visual contrast sensitivity is associated with regional cerebral tau deposition. Mean deviation in visual contrast sensitivity is
significantly associated with normal transformed [18F]flortaucipir SUVR in the MTL (A, P¼ 0.001), LTL (B, P< 0.001) and inferior parietal lobe
(C, P< 0.001) across all participants (n¼ 46). In addition, examination duration is associated with normal transformed [18F]flortaucipir SUVR in
the MTL (D, P¼ 0.006), LTL (E, P¼ 0.007) and inferior parietal lobe (F, P¼ 0.004) across all participants. Note that examination duration
(indicated as the natural log of seconds needed to complete the examination) is a measure of contrast sensitivity performance as the test is
iterative and those with poorer contrast sensitivity take longer on the examination, while lower mean deviation scores represent poorer
contrast sensitivity performance. Analysis includes 23 CN (blue circles), 12 SCD (green triangles), 9 MCI (yellow squares), and 2 AD (red
diamonds).
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sensitivity was associated with tau deposition in wide-
spread regions of the lateral temporal and parietal lobes
and the occipital lobe (Fig. 6B).
Predictive modelling
Using a logistic regression model, duration of examin-
ation alone significantly predicted cerebral amyloid posi-
tivity, with an overall accuracy of 75.7% (91.7%
specificity, 46.2% sensitivity; P< 0.001). The ROC ana-
lysis showed significant prediction of amyloid positivity
by examination duration with an area under the curve of
0.731 (Fig. 7A; P¼ 0.001). In SCD and MCI participants
only, examination duration, along with race/ethnicity,
predicted amyloid positivity with an overall accuracy of
86.1% (95.5% specificity, 71.4% sensitivity; P< 0.001).
In addition, the ROC analysis showed a significant pre-
diction of amyloid positivity by examination duration
with an area under the curve of 0.865 (Fig. 7C;
P< 0.001).
Mean deviation in contrast sensitivity significantly pre-
dicted tau positivity across all participants, with an over-
all accuracy of 82.6% (97.1% specificity, 36.4%
sensitivity; P¼ 0.003). The ROC analysis demonstrated a
significant prediction of tau positivity by mean deviation
in contrast sensitivity with an area under the curve of
0.735 (Fig. 7B; P¼ 0.020). The analyses in SCD and
MCI participants only showed a stronger prediction of
tau positivity with the combination of mean deviation in
contrast sensitivity and race/ethnicity showing an overall
accuracy of 90.5% (93.8% specificity, 80.0% sensitivity;
P< 0.001) in these at-risk individuals. Finally, the ROC
analysis also demonstrated a significant prediction of tau
positivity by mean deviation in contrast sensitivity with
an area under the curve of 0.863 (Fig. 7D; P¼ 0.017).
Discussion
In this study, we demonstrated that visual contrast sensi-
tivity, as measured via FDT, is associated with cerebral
deposition of amyloid and tau, as well as neurodegenera-
tion, across the spectrum of Alzheimer’s disease progres-
sion, as well as in at-risk groups only. Specifically, we
saw strong regional and global associations of amyloid
and tau, as well as temporal lobe atrophy, with visual
contrast sensitivity metrics, as well as a strong predictive
ability of contrast sensitivity measures to predict amyloid
and tau positivity. Overall, our findings suggest that vis-
ual contrast sensitivity may be a novel, inexpensive and
Figure 3 Visual contrast sensitivity is associated with regional cerebral tau deposition in SCD and MCI participants only. In
SCD and MCI participants only (n¼ 21), the mean deviation in visual contrast sensitivity is significantly associated with normal transformed
[18F]flortaucipir SUVR in the MTL (A, P¼ 0.001), LTL (B, P< 0.001) and inferior parietal lobe (C, P¼ 0.007). In addition, examination duration is
associated with normal transformed [18F]flortaucipir SUVR in the MTL (D, P¼ 0.011), LTL (E, P¼ 0.084) and inferior parietal lobe (F, P¼ 0.097).
Note that examination duration (indicated as the natural log of seconds needed to complete the examination) is a measure of contrast sensitivity
performance as the test is iterative and those with poorer contrast sensitivity take longer on the examination, while lower mean deviation scores
represent poorer contrast sensitivity performance. Analysis includes12 SCD (green triangles) and 9 MCI (yellow squares).
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easy-to-administer biomarker for Alzheimer’s disease-
related pathological changes.
Numerous studies have shown visual system dysfunc-
tion in patients with Alzheimer’s disease and MCI
(Albers et al., 2015). The most consistent findings are a
reduced retinal nerve fibre layer thickness in MCI and
Alzheimer’s disease (Coppola et al., 2015). Fewer studies
have addressed changes in retinal function, but deficits in
visual evoked potential, colour vision and other changes
have been observed (Frost et al., 2010; Albers et al.,
2015). The findings in this study add to the long litera-
ture on contrast sensitivity deficits in Alzheimer’s disease
(Cronin-Golomb et al., 1991; Cormack et al., 2000;
Crow et al., 2003; Risacher et al., 2013; Valenti, 2013;
Fischer et al., 2016; Polo et al., 2017; Ward et al.,
2018), by linking visual dysfunction not only with
clinical status but also with the underlying proteinopa-
thies thought to cause Alzheimer’s disease, thereby sug-
gesting that these relationships may be potential
underlying biological causes for previously observed defi-
cits in contrast sensitivity in those with or at risk for
Alzheimer’s disease.
The underlying cause of deficits observed in visual sys-
tem function and structure in MCI and Alzheimer’s dis-
ease is unknown. However, changes in both the retina
and brain could underlie some of these deficits. Recently,
a number of studies have suggested local accumulation of
amyloid-beta and tau deposits in the retina, both in ani-
mal models and post-mortem tissue (Koronyo-Hamaoui
et al., 2011; Chiasseu et al., 2017; Koronyo et al., 2017;
den Haan et al., 2018; Grimaldi et al., 2018). A previous
study in an Alzheimer’s disease animal model suggested
Figure 4 Visual contrast sensitivity is associated with temporal lobe volume. Significant associations between temporal lobe grey
matter volume and mean deviation in visual contrast sensitivity (A, P¼ 0.020) and examination duration (B, P¼ 0.003) were observed across all
participants (n¼ 74). Similar associations were observed when the analysis was limited to only the at-risk individuals (SCD and MCI participants;
n¼ 36), including significant associations between temporal lobe volume and mean deviation (C, P¼ 0.017) and examination duration (D,
P¼ 0.011). Note that examination duration (indicated as the natural log of seconds needed to complete the examination) is a measure of
contrast sensitivity performance as the test is iterative and those with poorer contrast sensitivity take longer on the examination, while lower
mean deviation scores represent poorer contrast sensitivity performance. A and B include 31 CN (blue circles), 20 SCD (green triangles), 16
MCI (yellow squares), and 7 AD (red diamonds); C and D include 20 SCD (green triangles) and 16 MCI (yellow squares).
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that amyloid accumulation in the retina occurs simultan-
eously with amyloid accumulation in the brain (Koronyo-
Hamaoui et al., 2011). In fact, a recent protocol to detect
these deposits in vivo has been recently reported and
reflects an exciting potential area for the biomarker de-
tection of Alzheimer’s disease (Klunk et al., 2015).
Furthermore, previous studies have suggested local dys-
function, neuroinflammation and loss of retinal ganglion
cells associated with tau aggregation in an animal model
(Chiasseu et al., 2017; Grimaldi et al., 2018). Thus, the
visual contrast sensitivity deficits that we observed in
the present study could be due to local degeneration of
Figure 5 Visual contrast sensitivity is associated with voxel-wise cerebral amyloid deposition. On the voxel-wise analysis, significant
associations between visual contrast sensitivity (examination duration) and amyloid deposition in the medial and lateral temporal and parietal
lobes, as well as focal regions of the occipital and frontal lobes, were observed both (A) across all participants (n¼ 74; 31 CN, 20 SCD, 16 MCI,
7 AD) or (B) SCD and MCI individuals only (n¼ 36). Note that examination duration (indicated as the natural log of seconds needed to
complete the examination) is a measure of contrast sensitivity performance as the test is iterative and those with poorer contrast sensitivity take
longer on the examination, while lower mean deviation scores represent poorer contrast sensitivity performance. Both analyses are displayed at
a voxel-wise threshold of P-value <0.05 (family-wise error correction for multiple comparisons) and minimum cluster size (k)¼ 10 voxels.
Figure 6 Visual contrast sensitivity is associated with voxel-wise cerebral tau deposition. Significant associations between mean
deviation in visual contrast sensitivity and tau deposition in the lateral and medial temporal and parietal lobes, as well as focal regions of the
occipital and frontal lobes, were observed both (A) across all participants (n¼ 46; 23 CN, 12 SCD, 9 MCI, 2 AD) or (B) SCD and MCI
individuals only (n¼ 21). The full sample analysis (A) is displayed at a voxel-wise threshold of P< 0.05 [family-wise error (FWE) correction for
multiple comparisons] and minimum cluster size (k)¼ 10 voxels. Note that lower mean deviation scores represent poorer contrast sensitivity
performance. *The SCD and MCI participants only sample (B) is displayed at a cluster-wise threshold of P-value <0.05 (FWE correction for
multiple comparisons), which is equivalent to P-value <0.001 (uncorrected) and minimum cluster size (k)¼ 400 voxels.
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retinal neuronal cells, including the retinal ganglion
cells, due to the accumulation of amyloid and tau
pathology.
Alternatively, amyloid and tau accumulation in the
brain may also potentially underlie the observed changes
in contrast sensitivity. The associations of contrast sensi-
tivity dysfunction with amyloid were strongest in poster-
ior regions of the brain, most especially the occipital
lobe. Although this area is not considered to be highly
impacted early in Alzheimer’s disease, amyloid accumula-
tion does occur in the occipital lobe (Thal et al., 2002).
These findings may suggest that at least part of the
contrast sensitivity deficits could be due to central amyl-
oid accumulation. Furthermore, the stereotypical progres-
sion of tau deposition beyond Braak stage 3 highly
overlaps with the ventral visual stream and other visual
association areas (Braak et al., 2006). Again, tau depos-
ition and associated neurodegeneration in these regions
may underlie at least part of the observed changes in vis-
ual contrast sensitivity performance. Future studies with
longitudinal FDT and neuroimaging, as well as visual
studies in animal models of Alzheimer’s disease, may help
us to better understand the underlying pathology causing
the observed changes in visual contrast sensitivity.
Figure 7 Receiver operating characteristic (ROC) curves for predicting amyloid and tau positivity by visual contrast
sensitivity. Visual contrast sensitivity (examination duration) significantly predicted amyloid positivity (defined as cortical Centiloid value
21.02) in the full sample (A; n¼ 74; AUC¼ 0.731, P¼ 0.001). In addition, visual contrast sensitivity (mean deviation) predicted tau positivity,
defined as assignment to Braak stage 4 (Schwarz et al., 2018), in the full sample (B; n¼ 46; AUC¼ 0.735, P¼ 0.020). In SCD and MCI
participants only, similar patterns were seen with examination duration predicting amyloid positivity (C; n¼ 36; AUC¼ 0.865, P< 0.001) and
mean deviation-predicted tau positivity (D; n¼ 21; AUC¼ 0.863, P¼ 0.017). AUC: area under the curve.
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This study has a few limitations. Although by far the
largest sample in a study of this type, the sample size is
relatively modest. In addition, the study is cross-sectional.
Future studies in a larger sample with longitudinal visual
examinations, neuroimaging and clinical follow-up are
warranted. The sample used in this analysis excludes
individuals with primary open-angle glaucoma, macular
degeneration and diabetic retinopathy, which are relative-
ly common in aging populations. Future studies testing
this tool in mixed samples of those with and without
concurrent eye disease would be needed to demonstrate
validity across a more clinically diverse set of individuals.
However, the current data suggest that, in this popula-
tion, visual contrast sensitivity on FDT is a good screen-
ing biomarker for the presence of Alzheimer’s disease
pathophysiology.
In sum, visual contrast sensitivity measures were
strongly associated with the presence of cerebral amyloid
and tau deposition. The findings suggest that visual con-
trast sensitivity should be explored further as an inexpen-
sive, non-invasive and easy-to-administer tool for
screening older adults for the presence of Alzheimer’s dis-
ease pathology, especially when combined with other risk
factors.
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